Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A2102 + adebrelimab vs gemcitabine + platinum in metastatic urothelial carcinoma (NEC-UC2)
CTR20260354Phase 3Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SHR-A2102, adebrelimab in transitional cell carcinoma (TCC), sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Feb 2026; status: active.
02
Drugs
SHR-A2102adebrelimab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20260354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260354.